An observational study in Retinal Degeneration, Retinitis Pigmentosa and Eye Diseases, Hereditary, sponsored by Jaeb Center for Health Research. Active, not recruiting at 10 sites in 8 countries. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Jaeb Center for Health Research · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 43 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.
Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 27th largest by enrollment of the 38 observational ones that give a count, is one of 11 that started in 2021, is one of 39 observational ones, reaches primary completion later than 18 of the 41 other live ones, and was the 85th registered.
281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.
Browse Retinitis Pigmentosa studies →20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:
Nacuity Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
Sumitomo Pharma America, Inc. · Sites in United States
Ages 18+
Octant, Inc. · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Retinitis Pigmentosa studies recruiting now, 38 (76%) set no upper age limit and 6 (12%) stop at 75 or younger; 16 take children under 18; 11 take healthy volunteers.
This study: 8 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 38 · Phase 3 11
First in 1993; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 52 across 89 observational studies indexed under Retinitis Pigmentosa.
Median enrollment 21 across the 78 interventional studies, 73 across the 38 observational. Of the 70 that completed or were terminated, 30 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 119 have an industry lead sponsor. The 10 most frequent:
Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Jaeb Center for Health Research has 3 studies filed under Retinitis Pigmentosa — fewer than ten, so there is no comparison to draw.
11 of the studies in Retinitis Pigmentosa with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06388200Phase 3OcugenA Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa | 2027-02-12 |
| NCT06912633jCyte, IncSafety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) | 2026-12 |
| NCT02086890Nova Southeastern UniversityElectro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa | 2026-12 |
| NCT04278131Bionic Sight LLCBS01 in Patients With Retinitis Pigmentosa | 2026-12-30 |
| NCT05748873SparingVisionPromising ROd-cone DYstrophy Gene therapY | 2027-02 |
Add all 11 to your calendar (.ics) → With an account.
Among the 119 studies in Retinitis Pigmentosa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall goal of this project, co-funded by the Foundation Fighting Blindness and the USHER 1F Collaborative is to characterize the natural history of disease progression in patients with PCDH15 mutations in order to accelerate the development of outcome measures for clinical trials.
This natural history study of patients with PCDH15 disease-causing variants will accelerate the development of outcome measures for clinical trials. Sensitive, reliable outcome measures of retinal degeneration will greatly facilitate development of treatments for retinitis pigmentosa due to PCDH15 disease-causing variants. Together these approaches are expected to have an impact on understanding PCDH15 related retinal degeneration, developing experimental treatment protocols, and assessing their effectiveness.
The goals and expected impact of this natural history study are to:
Study Objectives
The primary objectives of the natural history study are to:
281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.
This study's enrollment of 44 is below the median of 52 across 89 observational studies indexed under Retinitis Pigmentosa.
Browse Retinitis Pigmentosa studies →Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Compared within Retinitis Pigmentosa, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Retinal Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Study participants will be recruited from approximately 10 clinical sites worldwide. All eligible participants will be included without regard to gender, race, or ethnicity. Potential eligibility will be assessed during a routine examination by an investigator prior to obtaining informed consent, as part of usual care, through referrals from other providers or self-referral.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all the following inclusion criteria at the Screening Visit in order to be eligible to enroll into the genetic screening phase.
Must meet one of the Genetic Screening Criteria, defined below:
Note pertaining to all Screening Groups: if a participant has a variant(s) of unknown significance, he/she would still qualify if there is at least 1 disease-causing variant(s) on the PCDH15 gene. The Genetics Committee will review unique cases where segregation analysis is not feasible to determine eligibility.
Ocular Inclusion Criteria
Both eyes must meet all the following at the Screening Visit for a participant to be eligible to enroll into the genetic screening phase.
Exclusion Criteria:
Participants must not meet any of the following exclusion criteria at the Screening Visit in order to be eligible to enroll into the genetic screening phase.
Note: Pregnant women are not being specifically excluded from participation.
Ocular Exclusion Criteria
If either eye has any of the following at the Screening Visit, the participant is not eligible to enroll into the genetic screening phase.
History or evidence of active treatment for retinitis pigmentosa that could affect the progression of retinal degeneration, including:
\~25 participants with the better eye Screening Visit visual acuity ETDRS letter score of 54 or more \[approximate Snellen equivalent 20/80 or better\] and visual field diameter 10 degrees or more in every meridian of the central field. The better eye is defined as the eye with better Screening Visit ETDRS VA. If both eyes have the same VA (defined as the same Snellen equivalent), then the determination will be made at investigator discretion as the eye with better fixation or clearer ocular media to permit highest quality retinal imaging. The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to or including the Screening Visit date.
\~15 participants with the better eye Screening Visit visual acuity ETDRS letter score of 19-53 \[approximate Snellen equivalent 20/100 - 20/400\] or (visual acuity ETDRS letter score of 54 or more \[approximate Snellen equivalent 20/80 or better\] and visual field diameter less than 10 degrees in any meridian of the central field). The better eye is defined as the eye with better Screening Visit ETDRS VA. If both eyes have the same VA (defined as the same Snellen equivalent), then the determination will be made at investigator discretion as the eye with better fixation or clearer ocular media to permit highest quality retinal imaging. The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to or including the Screening Visit date.
Change in Visual Field Sensitivity
measured by static perimetry with quantitative, topographic analysis (Hill of Vision) and assessed by a central reading center
Time frame: Baseline (all Vision Cohort 1 and 2 participants will complete two tests at baseline. The results will be compared according to the visual field criteria to determine if a third test is needed), 12Month, 24Month, 36Month, and 48Month
Change in Best Corrected Visual Acuity
Early Treatment of Diabetic Retinopathy Study (ETDRS) Best corrected visual acuity (BCVA) letter score as measured on the Electronic Visual Acuity (EVA) system or ETDRS charts. Letter score range values=0-100 (with higher values = better and lower values = worse.) Berkeley Rudimentary Vision Test (BRVT) will be used for patients unable to see letters.
Time frame: Screening, Baseline, 12Month, 24Month, 36Month, and 48Month
Change in Mean Retinal Sensitivity
Measured by fundus-guided microperimetry (MP) and assessed by a central reading center at selected sites with requisite equipment.
Time frame: Baseline (all Vision Cohort 1 and 2 participants will complete two tests at baseline. The results will be compared according to the visual field criteria to determine if a third test is needed), 12Month, 24Month, 36Month, and 48Month
Change in Full-field Retinal Sensitivity
Measured by full-field stimulus threshold (FST) testing to blue, white and red stimuli.
Time frame: Baseline, 12Month, 24Month, 36Month, and 48Month
Change in Best Corrected Low Luminance Visual Acuity (LLVA)
Measured by Letter Score. Letter score range values=0-100 (with higher values = better and lower values = worse.)
Time frame: Screening, Baseline, 12Month, 24Month, 36Month, and 48Month
Change in Contrast Sensitivity Function (CSF)
Measured by the CSV-1000E VectorVision chart
Time frame: Baseline, 12Month, 24Month, 36Month, and 48Month
Change in ellipsoid zone (EZ) area
Measured by spectral domain optical coherence tomography (SD-OCT) and assessed by a central reading center.
Time frame: Baseline, 12Month, 24Month, 36Month, and 48Month
Explore qualitative categorization of Fundus Autofluorescence (FAF) pattern
Assessed by a central reading center.
Time frame: Baseline, 12Month, 24Month, 36Month, and 48Month
Explore quantitative measures of FAF
Assessed by a central reading center.
Time frame: Baseline, 12Month, 24Month, 36Month, and 48Month
Patient Reported Outcomes (Adults 18 years or older)
Measured by Michigan Retinal Degeneration Questionnaire (MRDQ) MRDQ - consists of 59 items using categories: : ''None: I do not have trouble with this,'' ''A little difficulty: I notice a problem, but I do not struggle,'' ''Moderate difficulty: I struggle but I can still do this,'' ''Extreme difficulty : I struggle a lot and sometimes I cannot do this,'' and ''N/A for non-vision reasons: I do not do this.'
Time frame: Baseline, 24Month, and 48Month
Patient Reported Outcomes (Adults 18 years or older)
Measured by Patient-Reported Outcomes Measurement Information System (PROMIS®-29)
Time frame: Baseline, 24Month, and 48Month
Patient Reported Outcomes (less than 18 years):
L. V. Prasad-Functional Vision Questionnaire (LVP-FVQ II) The LVP-FVQ II consists of 23 items using 3 categories: 1, no difficulty; 2, some difficulty; 3, a lot of difficulty
Time frame: Baseline, 24Month, and 48Month
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — A de-identified database is placed in the public domain on the FFB/Jaeb public website after the completion of each protocol and publication of the manuscript.
Supporting information: Study protocol, Informed consent form
Time frame: After manuscript is published
Access criteria: Users accessing data must enter an email address
Started Jun 2021 (actual). Primary completion is estimated for Jun 2027, 72 months after the start.
Of 49 observational studies under Retinitis Pigmentosa, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 23. This study's planned 72 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jaeb Center for Health Research →